Boston Scientific Stock News

Boston Scientific (BSX) delivered earnings and revenue surprises of 2.27% and 0.91%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Boston Scientific (NYSE:BSX) is scheduled to announce Q4 earnings results on Wednesday, February 2nd, before market open.The consensus EPS Estimate is $0.44 (+91.3% Y/Y) and the

Medical Products companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BSX, TMO, HOLX and MCK are poised ahead of their earnings releases.

Boston Scientific is scheduled to report its Q4 2021 results on Wednesday, Feb 2. We expect the company to report revenues in-line but earnings marginally below the consensus estimates, as the rise of

Dublin, Jan. 31, 2022 (GLOBE NEWSWIRE) -- The "Urinary Incontinence Market by Product, Incontinence Type, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com''s offering. The global urinary incontinence market was valued at $10,124.33 million in 2020, and is projected to reach $19,341.15 million by 2030, registering a CAGR of 6.8% from 2021 to 2030. The involuntary flow of urine due to a loss of bladder control is known as urinary incontinence. Urinary incontinence devices aid in collecting and holding urine; such devices help in managing urinary incontinence effectively. People undergoing urinary incontinence suffer from urine leakage that cannot be controlled. Patients suffering from severe urinary incontinence are recommended surgical treatment that incorporates devices such as urinary catheter, vaginal slings, electrical stimulation devices, and artificial urinary sphincters. Among the aforementioned incontinent devices, the most evidently used devices include indwelling catheters, external collecting systems, urine drainage bags, and catheters for intermittent catheterization (IC).

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.

On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.

DUBLIN , Jan. 25, 2022 /PRNewswire/ -- The "Urinary Incontinence Market by Product, Incontinence Type, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com''s offering. The global urinary incontinence market was valued at $10,124.33 million in 2020, and is projected to reach $19,341.15 million by 2030, registering a CAGR of 6.8% from 2021 to 2030. The involuntary flow of urine due to a loss of bladder control is known as urinary incontinence. Urinary incontinence devices aid in collecting and holding urine; such devices help in managing urinary incontinence effectively. People undergoing urinary incontinence suffer from urine leakage that cannot be controlled. Patients suffering from severe urinary incontinence are recommended surgical treatment that incorporates devices such as urinary catheter, vaginal slings, electrical stimulation devices, and artificial urinary sphincters. Among the aforementioned incontinent devices, the most evidently used devices include indwelling catheters, external collecting systems, urine drainage bags, and catheters for intermittent catheterization (IC).

Although Boston Scientific (BSX) reports margin expansion on a year-over-year basis, the decline in R&D expenses is concerning.

Although Boston Scientific (BSX) reports margin expansion on a year-over-year basis, the decline in R&D expenses is concerning.

Major neurostimulation devices market players include Abbott, Boston Scientific, IntraPace, Laborie, LivaNova, Medtronic, Neuronetics, SPR Therapeutics, Cyberonics, ElectroCore Inc., Aleva Neurotherapeutics SA, Synapse Biomedical Inc., MicroTransponder, RS Medical, Helbling holding Ag, EndoStim Inc., and BioControl Medical. SELBYVILLE, Del. , Jan. 20, 2022 /PRNewswire/ -- The neurostimulation devices market size is anticipated to record a valuation of USD 13.6 billion by 2027, according to the most recent study by Global Market Insights Inc. Increasing adoption and introduction of advanced neurostimulation devices will drive the overall market growth. Increasing demand for minimally invasive surgeries in developed countries attributed to the rising preference among patients for shorter hospital stays and faster recovery will accelerate the neurostimulation devices market expansion. Neurological patients using minimally invasive techniques, have experienced reduced treatment costs, less pain, and speedy recovery.

Los Angeles, USA, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Spinal Cord Stimulators Market is Contemplated to Surge at a CAGR of 8.69% and is Anticipated to Reach Upto USD 3.42 Billion by 2026, Estimates DelveInsight Spinal Cord Stimulators market is expected to surge in the coming years due to the growing number of patients with chronic pain, neuropathic pain in the shoulder, legs, and knee, along with the introduction of technologically advanced devices that are non-invasive, eliminate targeted pains, are expected to drive the Spinal Cord Stimulators market. DelveInsight''s Spinal Cord Stimulators Market Insights and Forecast report provides the current and forecast Spinal Cord Stimulators Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Spinal Cord Stimulators Market. Some of the salient features from the Spinal Cord Stimulators Market report: As per DelveInsight analysis, in terms of revenue share, North America is predicted to register the fastest growth in the Spinal Cord Stimulators market.